## LRCX: Lam Research Corporation - XLK: Technology

### Executive Summary

No thesis match: MRS_10 1.1% below STRENGTH zone (3.0-6.0%); PEG 2.20 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($143.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Lam Research Corporation (LRCX): A Bull Case Theory**
- Source: Finviz | 20251204T141800 | Somewhat-Bullish | Relevance: 100%
- This article summarizes a bull thesis on Lam Research Corporation (LRCX), a leading semiconductor equipment company. Although the stock has appreciated significantly in 2025, the analyst maintains a Hold rating with an accumulation recommendation below $110, viewing Lam as a long-term compounder. The company's strong financial performance, leadership in etch and deposition tools, and robust future growth prospects are highlighted.

**2. Stocks making big moves yesterday: Lam Research, Sweetgreen, Applied Materials, Lattice Semiconductor, and The Pennant Group**
- Source: Finviz | 20251203T080000 | Bullish | Relevance: 100%
- This article details the significant stock movements of five companies on Tuesday: Lam Research, Sweetgreen, Applied Materials, Lattice Semiconductor, and The Pennant Group. Each company experienced a rise in stock value due to various positive developments, including analyst upgrades, raised price targets, expansion news, and strong "Buy" ratings. The report highlights the specific catalysts behind each company's stock appreciation.

**3. Scotia Capital Inc. Sells 9,284 Shares of Lam Research Corporation $LRCX**
- Source: MarketBeat | 20251202T122309 | Neutral | Relevance: 100%
- Scotia Capital Inc. reduced its stake in Lam Research Corporation ($LRCX) by 45% in the second quarter, selling 9,284 shares and retaining 11,362 shares valued at $1.11 million. This comes as Lam Research reported strong earnings, beating revenue and EPS estimates, and provided positive Q2 2026 guidance. Insider selling has been significant, with 102,608 shares offloaded in the past three months, reducing insider ownership to 0.31%.

**4. Lam Research (LRCX) Stock Is Up, What You Need To Know**
- Source: Finviz | 20251202T111100 | Somewhat-Bullish | Relevance: 100%
- Shares of Lam Research (NASDAQ:LRCX) jumped 2.9% after Morgan Stanley raised its price target to $158 from $137, maintaining an "Equalweight" rating. This optimistic outlook on the semiconductor equipment maker's valuation comes amidst renewed investor interest and strong financial performance. The stock's performance reflects its volatility and the market's positive, yet cautious, reception to significant news, like the broader tech sector uplift driven by AI developments and potential interest rate cuts.

**5. Wall Street Bulls Look Optimistic About Lam Research (LRCX): Should You Buy?**
- Source: Finviz | 20251204T170804 | Somewhat-Bullish | Relevance: 100%
- Wall Street analysts are optimistic about Lam Research (LRCX), with an average brokerage recommendation (ABR) of 1.69, suggesting a strong buy. However, the article advises against relying solely on ABR due to potential positive bias from brokerage firms and instead recommends using the Zacks Rank, which indicates a Zacks Rank #2 (Buy) for LRCX due to recent positive earnings estimate revisions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $158 | $137 | +15% |
| 2025-11-25 | UBS | $175 | $165 | +6% |
| 2025-11-12 | Citigroup | $190 | $175 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Equal-Weight |
| 2025-11-25 | UBS | main | Buy |
| 2025-11-12 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 12 ($2.00M) |
| Sells | 6 ($14.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+0.3%)
- Blackrock Inc.: 9.9% (+1.7%)
- JPMORGAN CHASE & CO: 4.8% (+47.4%)
- State Street Corpora: 4.8% (+0.4%)
- Geode Capital Manage: 2.7% (-0.5%)

### Key Risks

1. Heavy insider selling: $15M sold (6 transactions in 90 days).
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.20 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 62%, ROA 20%, margin 30%). Balance sheet: strong liquidity (2.2x), $1.6B free cash flow. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($14.5M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $224.6B |
| Beta | 1.78 |
| 52W Range | $56.32 - $179.80 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.20 |
| Forward P/E | 27.9 |
| Current P/E | 32.4 |
| YoY Growth | 16.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.4% to 1.1% (-1.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.9pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.15% (CS: 64) | Neutral |
| RSI_14 | 55.2 | Neutral |
| MACD Histogram | 0.38 | Bullish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 1.511x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $157.09
- **Stop Loss:** $143.97 (8.4% risk)
- **Target:** $170.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 76
- **Position Value:** $11,938.84
- **Portfolio %:** 11.94%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-01-28 (Est: $1.16)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.22 | $1.26 | +3.3% |
| 2025Q2 | $1.21 | $1.33 | +10.4% |
| 2025Q1 | $1.00 | $1.04 | +4.1% |
| 2024Q4 | $0.88 | $0.91 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*